New Chronic Rhinosinusitis Treatment Algorithm Released by Expert Panel

In response to new FDA-approved treatments for chronic rhinosinusitis with nasal polyps (CRSwNP), a group of experts has developed a stepwise treatment paradigm for patients with the condition.

The scientific committee was made up of 11 experts, including both otolaryngologists and allergists, as well as members of societies with an interest in the treatment of patients with CRSwNP (American Rhinologic Society [ARS], American Academy of Allergy Asthma and Immunology [AAAAI], American Academy of Otolaryngology & Head and Neck Surgery [AAOHNS], American College of Allergy Asthma and Immunology [ACAAI], and American Academy of Otolaryngic Allergy [AAOA]), conducted a literature search of data on FDA approved treatment options for CRSwNP from January 2000 through December 2020.

The committee discussed each treatment option’s safety and efficacy, as well as its limitations. Using the data, they developed a clinical care pathway for the treatment of patients with CRSwNP.

Treatment options reviewed by the committee include:

  • Intranasal corticosteroids
  • Exhalation delivery devices
  • Ethmoid sinus steroid-eluting implants
  • Monoclonal antibody therapies
  • Biologics


The authors note that the opinions in this algorithm are theirs alone, and do not necessarily reflect those of the organizations that they are members of, and that treatment decisions should be made using shared decision making with patients.

“Shared decision making throughout this process is advocated in order to determine patient preferences and availability as well as cost of therapeutic options. A thoughtful discussion including risks and benefits of each option is important in order to achieve the best outcome for the patient.”

—Michael Potts


Han JK, Bosso JV, Cho SH, et al. Multidisciplinary consensus on a stepwise treatment algorithm for management of chronic rhinosinusitis with nasal polyps. Int Forum Allergy Rhinol. Published online May 31, 2021.